In a sector with a great growth potential such as the sector of the pharmaceutical industry, SIPHAT maintains its position of leader of the Tunisian industrial network and is its main component. The stability of its position is the fruit of a strategy based mainly on the variety of its production range: 141 officinal products, 109 hospital products and 135 patent medicines grouped in about fifteen therapeutic classes ensuring quality assurance.
Production capacity
Production sites | Production capacity in millions of units |
Dry forms | 500 (tablets) 10 (capsules) 3 (Sachets) |
Pasty forms | 4.5 (Tubes) 56 (suppositories) |
Liquid forms | 25 (drinkable phials) 6 (perfusable bags) 5.6 (syrup flasks) 2.5 (litters of concentrated solutions for haemodialysis) 1.5 perfusable solution bottles 3 injectables ampoules |
Name | DCI |
---|---|
Anaspasme | Phloroglucinol |
Metrogyl | Metromidazol |
Fenothyl | Fenofibrate |
Ramitec | Ramipril |
Prazor | Lansoprazole |
CARDIOLOGIE AND ANGIOLOGIE | ||